The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.
(S)-(4,5-DIHYDRO-7H-THIENO[2,3-C]PYRAN-7-YL)-N-METHYLMETHANAMINE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS